10-K/A: Cardiff Lexington Faces Deep Losses, Going Concern

Cardiff Lexington Corporation reported a significant net loss and negative operating cash flow for 2024, raising substantial doubt about its ability to continue as a going concern, despite securing an increased line of credit.

Summary

• Cardiff Lexington Corporation, an acquisition holding company primarily in healthcare and real estate, reported a net loss of $3,302,999 for the year ended December 31, 2024, a significant decline from a net income of $3,028,394 in 2023.
• Total revenue decreased by 30.23% to $8,270,126 in 2024 from $11,853,266 in 2023, primarily due to a shift to lower-revenue pain management treatments and a reduced settlement realization rate in its healthcare segment.
• The healthcare segment's average settlement rate of gross billed charges decreased from 49% to 44% in 2024, leading to a $1,005,764 reduction in net revenue and a $1,650,474 change in accounting estimate.
• Gross profit fell by 46.60% to $4,428,498 in 2024, with gross margin decreasing from 69.96% to 53.55%.
• Operating expenses increased by 49.21% to $4,622,002 in 2024, driven by higher share-based compensation ($544,725), salaries and wages ($714,799 increase), bad debt expense ($133,719 increase), legal fees ($105,152 increase), public company and investor relations fees ($106,820 increase), and rent expense ($130,331 increase).
• Net cash used in operating activities increased to $2,765,797 in 2024 from $1,807,987 in 2023, indicating an accelerated cash burn from operations.
• The company's independent registered public accounting firm included a going concern explanatory paragraph, citing recurring operating losses and negative cash flows, which raise substantial doubt about its ability to continue operations.
• Management believes current working capital and expected additional financing should be sufficient for at least one year, but acknowledges the need for $600,000 to $1 million for continued operations and $4 million to $10 million for business plan execution and acquisitions.
• The company increased its revolving line of credit with DML HC Series, LLC from $4.5 million to $15 million, with an outstanding balance of $8,645,991 as of December 31, 2024.
• Material weaknesses in internal control over financial reporting were identified, including lack of formal documentation, proper segregation of duties, and sufficient technical accounting resources for complex transactions.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by a substantial net loss, negative operating cash flow, and a going concern warning from its auditor. Revenue is declining, expenses are rising, and internal control weaknesses are noted. While a line of credit has been increased, the underlying business performance is deteriorating, and significant capital is still needed for operations and growth, making the outlook highly unfavorable.

Positives

• Secured an increased revolving line of credit with DML HC Series, LLC, raising the maximum advance amount from $4.5 million to $15 million, providing access to additional liquidity.
• Management is actively implementing enhanced practices to better capture and manage the aging of accounts receivables, which is expected to improve financial systems over 18-24 months.
• The company has established a 401(k) plan for employees in 2024, indicating a commitment to employee benefits.
• The company has a stated strategy of acquiring undervalued and undercapitalized healthcare companies, which could provide future growth opportunities if successfully executed and funded.

Negatives

• Reported a net loss of $3,302,999 in 2024, a significant deterioration from a net income of $3,028,394 in 2023.
• Revenue decreased by 30.23% in 2024, primarily due to lower settlement realization rates from surgical procedures and an increase in lower-revenue pain management treatments.
• Gross profit declined by 46.60% and gross margin significantly compressed from 69.96% to 53.55% in 2024, indicating reduced profitability per dollar of revenue.
• Operating expenses increased substantially by 49.21% in 2024, outpacing revenue, contributing to the increased net loss.
• Net cash used in operating activities increased to $2,765,797 in 2024, reflecting an accelerating cash burn from core operations.
• The company has an accumulated deficit of $72,949,085 as of December 31, 2024, and the auditor's report includes a going concern explanatory paragraph.
• The accounts receivable collection lifecycle is extended (18-24 months), creating liquidity and cash flow constraints, increased exposure to bad debt, and dependence on external financing.
• Identified material weaknesses in internal control over financial reporting, including lack of formal documentation, proper segregation of duties, and sufficient technical accounting resources for complex debt and equity transactions.
• The company's healthcare facilities are operating at only 35% capacity as of December 31, 2024, indicating significant underutilization.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring operating losses and negative cash flows.
• Extended accounts receivable collection lifecycle (18-24 months) creates liquidity and cash flow constraints, increases exposure to bad debt, and necessitates reliance on external financing.
• Lack of systematic processes and resources to support the aging of accounts receivables, leading to inefficiencies and potential inaccuracies in financial reporting.
• Acquisition strategy exposes the company to substantial risks, including failure to identify material problems during due diligence, overpaying for assets, and difficulties in integrating acquired businesses.
• Inability to successfully fund acquisitions due to unavailability of equity or debt financing on acceptable terms, which could impede the implementation of the acquisition strategy.
• Management and acquisition strategies may change without stockholder consent, potentially leading to riskier business activities.
• Reliance on distributions and other payments from subsidiaries to meet obligations, which may be subject to limitations.
• Potential exposure to additional risks associated with leverage and restrictive covenants if new credit facilities are entered into.
• Loss of services of current officers and directors could severely impact business operations and future development.
• Future success is dependent on the management teams of its businesses, and the loss of any key personnel could materially adversely affect financial condition.
• Potential conflicts of interest may arise from business transactions with target businesses that have relationships with executive officers, directors, or their affiliates.
• Operational objectives and business plans of subsidiaries may conflict with corporate objectives, creating competing demands for resources.
• Risk of being deemed an investment company under the Investment Company Act if the company ceases to control and operate its businesses or engages in certain investment-related activities.
• Changes to payment rates or methods of third-party payors, including government healthcare programs, could adversely affect operating margins and revenues.
• Increase in uninsured or underinsured patients or deterioration in collectability of accounts could harm results of operations.
• Failure to timely or accurately bill for services could negatively impact net revenue and cash flow.
• Intense competition for patients, physicians, and staff in the healthcare industry, potentially increasing labor costs and reducing patient volume.
• Failure to continually enhance facilities with recent technological advances in diagnostic and surgical equipment could adversely affect market position.
• Non-compliance with extensive healthcare laws and government regulations could result in civil or criminal penalties or require significant operational changes.
• Subject to occupational health, safety, and environmental regulations, with failure to comply potentially harming business and results.
• Substantial expenditures may be required to comply with statutes and regulations relating to privacy and security of protected health information (HIPAA, HITECH).
• State efforts to regulate the construction or expansion of healthcare facilities (CON laws) could impair expansion ability.
• Cybersecurity incidents could cause HIPAA violations, breach of privacy, or other negative impacts.
• Failure to deal with clinical waste in accordance with regulations or breach of medical, health, and safety laws could lead to liability, fines, or license suspension.
• Risk of losing accreditation for healthcare facilities, making them ineligible for Medicare or Medicaid reimbursement.
• Exposure to lawsuits, including medical malpractice and professional liability claims, for which the company may not be fully reserved.
• Demand fluctuations in the real estate industry could adversely affect business, results of operations, and financial condition.
• Adverse weather conditions, natural disasters, and unforeseen geological conditions could disrupt real estate developments.
• Decrease in the market value of real estate investments could reduce results of operations.
• Changes in tax laws, taxes, or fees may increase the cost of real estate development.
• High competition in the real estate industry from entities with greater financial resources.
• Incurrence of environmental liabilities with respect to real estate assets.
• Co-venture partners or other co-ownership arrangements could take actions that decrease the value of real estate assets.
• Uninsured losses relating to real property or excessively expensive premiums for insurance coverage may adversely affect stock value.
• Common stock quotation on the Pink Market may result in unfavorable impact on stock price and liquidity.
• Significant price volatility of common stock due to sporadic/thin trading and speculative nature of investment.
• Officers and directors own a significant percentage (84.69%) of voting securities, reducing minority stockholders' ability to effect corporate actions.
• No current plans to pay cash dividends on common stock for the foreseeable future.
• Future issuances of common stock or convertible securities could cause market price to decline and result in dilution.
• Rule 144 sales in the future may have a depressive effect on stock price.
• Future issuances of debt or preferred stock could rank senior to common stock, adversely affecting return.
• If shares become subject to penny stock rules, it would become more difficult to trade.
• Lack of research reports from securities industry analysts could negatively affect market price and trading volume.
• Ongoing public reporting requirements are less rigorous than for larger companies, potentially making securities less attractive.
• Anti-takeover provisions in charter documents and Nevada law could make an acquisition more difficult.

Future Outlook

Management believes current working capital and expected additional financing should be sufficient to fund operations and satisfy obligations for at least one year. The company requires $600,000 to $1 million for continued operations and $4 million to $10 million for executing its business plan and acquiring additional businesses, with the amount dependent on sellers' willingness to accept non-cash consideration. The company intends to raise capital for additional acquisitions primarily through equity and debt financings. It plans to continue evaluating its settlement realization rates monthly and updating estimates quarterly. The company's growth strategy includes capitalizing on organic growth opportunities at existing facilities (currently at 35% capacity) and supplementing this with strategic acquisitions, focusing on outpatient Orthopedic Surgery Centers and related Clinics in 18 identified states.

Management Comments

• Management believes, based on our operating plan, that current working capital and current and expected additional financing should be sufficient to fund operations and satisfy our obligations as they come due for at least one year from the financial statement issuance date.
• Management has invested years working to develop a new and exciting housing development in Salmon, Idaho and plans to enter into a joint venture agreement with a developer for this planned concept development.
• We believe that the most important factors relating to the overall utilization of a facility include adequate working capital, the quality and market position of the facility and the number, quality and specialties of physicians providing patient care within the facility.
• We believe that we have superior access to patient information to determine the validity of each case and manage cases appropriately.
• We believe that we have several competitive advantages that differentiate us from other holding companies, including management operating and investing experience, an extensive network of small to middle market companies, public company benefits, and maintaining day-to-day control of operations.
• We believe there to be a significant opportunity for organic growth and expanded utilization of our current locations and an opportunity to open additional locations within new markets.
• We further believe the economic and market dislocation resulting from the COVID-19 pandemic enhanced our opportunity to obtain potentially profitable businesses, which are facing lingering working capital challenges post pandemic, but have rebounded and returned to or near previous levels of profitability.
• We believe the expertise and relationships of our management team represent a compelling value proposition for potential business targets looking for additional working capital infusion, a pathway to exit some equity, and leadership to assist them to grow and expand.
• We are in the process of implementing enhanced practices to better capture and manage the aging of its billings for accounts receivable. However, these practices are not yet fully operational.
• We are making necessary changes by making strategic hiring decisions and providing training to our financial team, and other relevant personnel, on the GAAP accounting guidelines applicable to financial reporting requirements.
• We are implementing proper documentation procedures for key functional areas, control objectives and our workflows.
• We are enhancing our processes, routine and non-routine, to encompass segregation of duties as well as oversight of secondary independent reviews.
• We plan to reinforce effective compensating controls to improve the design of the current process with limited human resources.
• We hired external consultants to assist with our assessment and accounting for variable consideration as accounted for under ASC 606 and our credit loss expense as accounted for under ASC 326.

Industry Context

The company operates primarily in the healthcare sector, specifically regional primary specialty and ancillary care facilities in Florida focusing on traumatic injury victims and plaintiff-related care. This niche is partially insulated from declining Medicare/Medicaid and traditional health insurance reimbursements, relying instead on bodily injury, general liability, and personal injury protection policies. However, the industry faces intense competition, cost containment pressures, and staffing shortages (exacerbated by COVID-19). The company's real estate segment is focused on residential development in Salmon, Idaho, a market subject to local economic conditions and environmental regulations. The company's strategy of acquiring undervalued, undercapitalized businesses is a common private equity approach, but its reliance on extended accounts receivable cycles (18-24 months) in the lien-based medical industry presents unique liquidity challenges not typically seen in traditional product/service businesses.

Comparison to Industry Standards

• The company's accounts receivable collection cycle of 18 to 24 months is significantly longer than the typical 30, 60, or 90-day increments for traditional product or service businesses, which strains liquidity and cash flow.
• The healthcare facilities operating at 35% capacity as of December 31, 2024, indicates substantial underutilization compared to industry benchmarks for efficient healthcare operations, which typically aim for higher occupancy rates to maximize revenue and cover fixed costs.
• The decline in gross margin from 69.96% in 2023 to 53.55% in 2024 suggests a significant erosion of profitability per service, potentially indicating a less favorable competitive position or pricing power compared to industry leaders.
• The company's reliance on lien-based medical services, where payment is contingent on legal settlements, differs from standard healthcare provider models that typically receive direct payments from insurers or government programs, introducing unique risks related to legal outcomes and prolonged collection periods.
• The identified material weaknesses in internal controls over financial reporting (lack of formal documentation, segregation of duties, technical accounting resources) fall below standard corporate governance practices for publicly traded companies, potentially impacting financial reporting reliability compared to well-controlled peers.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to claims and suits in the ordinary course of business, including those arising from services provided, personal injury claims, professional liability claims, billing and marketing practices, employment disputes, and contractual claims.
• Management is not currently aware of any legal proceedings or claims that are believed to have a material adverse effect on the company's business, financial condition, or operating results.

Related Party Transactions

• Short-term advances from Daniel Thompson, Chairman of the Board, which were non-interest bearing and due on demand. The outstanding balance of $120,997 as of December 31, 2023, was repaid in full during 2024.
• Amounts due to previous owners who are current managers of Edge View (real estate subsidiary) totaling $4,979 as of December 31, 2024 and 2023, which are due on demand and do not bear interest.
• Issuance of 62,500 shares of series I preferred stock to Daniel R. Thompson (Chairman) and Alex Cunningham (CEO) on January 19, 2024, for $250,000 bonus compensation for fiscal year 2023.
• Issuance of a twelve-month convertible promissory note in the principal amount of $5,000 to the CEO on August 25, 2023, for operating expenses, which was paid in full in August 2024.
• Compensation arrangements for executive officers and directors, including base salaries, bonuses, and stock awards, as detailed in the Summary Compensation Table and Employment Agreements.

Stakeholder Impact

• **Shareholders**: Face significant risk of investment loss due to recurring operating losses, negative cash flow, and a going concern warning. Potential for dilution from future equity raises. Price volatility and limited liquidity on the Pink Market are concerns. Concentration of voting power by officers and directors limits minority shareholder influence.
• **Employees**: Benefit from the establishment of a 401(k) plan. However, the company's financial instability and need for cost reductions could impact job security or future compensation. Staffing shortages in the healthcare segment may lead to increased workload or reliance on temporary labor.
• **Customers (Patients)**: The extended accounts receivable collection cycle and focus on lien-based care may impact patient experience or access to services, though the company states it provides a full range of diagnostic and surgical services for traumatic injury victims.
• **Suppliers/Creditors**: The company's liquidity constraints and dependence on external financing, coupled with a going concern warning, increase credit risk for suppliers and lenders. The extended accounts receivable cycle could also impact timely payments to vendors.
• **Management**: Faces pressure to improve financial performance, secure additional funding, and address internal control weaknesses. Compensation includes significant stock awards and potential bonuses tied to performance and capital raises, aligning their interests with company growth, but also exposing them to financial risks.

Next Steps

• Continue efforts to accelerate cash settlement of accounts receivable, potentially by accepting lower settlement amounts.
• Implement enhanced practices to better capture and manage the aging of accounts receivables, with an expected 18-24 month lag for full data availability.
• Make necessary changes, including strategic hiring and training, to address material weaknesses in internal controls over financial reporting.
• Reinforce effective compensating controls to improve current processes with limited human resources.
• Continue to evaluate estimates of settlement realization rates monthly and update quarterly.
• Capitalize on organic growth opportunities at existing healthcare facilities (currently at 35% capacity).
• Supplement organic growth with strategic acquisitions, focusing on outpatient Orthopedic Surgery Centers and related Clinics in 18 identified states.
• Enter into a joint venture agreement with a developer for the planned housing development in Salmon, Idaho.
• Pursue new financing and/or future equity raises to fund cash flow shortfalls and new acquisitions, with an estimated need of $4 million to $10 million.

Key Dates

Recommendation

The company's financial performance has severely deteriorated, marked by a substantial net loss, a significant decline in revenue and gross profit, and increasing operating expenses in 2024. The auditor's explicit 'going concern' warning, coupled with persistent negative operating cash flows and a large accumulated deficit, indicates a high probability of financial distress or failure. While the company has secured an increased line of credit, this merely provides short-term liquidity without addressing the fundamental issues of declining revenue quality (lower settlement rates) and operational inefficiencies. The identified material weaknesses in internal controls further undermine confidence in financial reporting. Given these severe financial and operational challenges, and the high risk of further dilution or cessation of operations, a seasoned investor would likely recommend a strong sell.

Keywords

Healthcare, Real Estate, Acquisition Holding Company, SEC Filing, 10-K/A, Financial Performance, Net Loss, Operating Cash Flow, Going Concern, Accounts Receivable, Settlement Rates, Internal Controls, Corporate Governance, Convertible Debt, Line of Credit, Risk Factors, Nevada Corporation, OTC Pink Market